drugset / Trial / NCT03851731

Evaluation of Intranasal Naltrexone and Naloxone

NCT03851731

Phase 1 Completed 12 enrolled National Institute on Drug Abuse (NIDA)
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will be to determine the pharmacokinetics of naltrexone and naloxone when administered via intranasal separately and in combination in healthy volunteers.

Timeline

Start
2015-10-05
Primary completion
2015-11-07
Completion
2015-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 4 mg Intranasal
Subject Naltrexone Small molecule 2 mg Intranasal